Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey NL 64460, Mexico.
Departament of Basic Science, School of Medicine, Universidad de Monterrey, Av. Ignacio Morones Prieto 4500 Pte, Garza García NL 66238, Mexico.
Viruses. 2020 Feb 13;12(2):208. doi: 10.3390/v12020208.
The expansion of the habitat of mosquitoes belonging to the genus puts nearly half of the world's population at risk of contracting dengue fever, and a significant fraction will develop its serious hemorrhagic complication, which can be fatal if not diagnosed properly and treated in a timely fashion. Although several diagnostic methods have been approved for dengue diagnostics, their applicability is limited in rural areas of developing countries by sample preparation costs and methodological requirements, as well as cross-reactivity among the different serotypes of the Dengue virus and other flavivirus, such as the Zika virus. For these reasons, it is necessary to generate more specific antigens to improve serological methods that could be cheaper and used in field operations. Here, we describe a strategy for the inactivation of cross-reacting epitopes on the surface of the Dengue virus envelope protein through the synthetic generation of recombinant peptide sequences, where key amino acid residues from Dengue virus serotype 1 (DENV-1) and 2 (DENV-2) are substituted by alanine residues. The proteins thus generated are recognized by 88% of sera from Dengue NS1+ patients and show improved serotype specificity because they do not react with the antibodies present in seroconverted, PCR-serotyped DEN-4 infected patients.
蚊子属的栖息地不断扩大,使近一半的世界人口面临感染登革热的风险,其中相当一部分人将出现严重的出血并发症,如果不能及时正确诊断和治疗,可能致命。尽管已经批准了几种用于登革热诊断的方法,但由于样品制备成本和方法要求,以及登革病毒和其他黄病毒(如寨卡病毒)之间的不同血清型的交叉反应性,这些方法在发展中国家的农村地区的适用性有限。出于这些原因,有必要生成更具特异性的抗原,以改进血清学方法,这些方法可能更便宜,并可用于现场操作。在这里,我们描述了一种通过合成产生重组肽序列使登革病毒包膜蛋白表面的交叉反应表位失活的策略,其中登革病毒血清型 1(DENV-1)和 2(DENV-2)的关键氨基酸残基被丙氨酸残基取代。由此产生的蛋白质可被 88%的登革热 NS1+患者血清识别,并显示出改善的血清型特异性,因为它们不会与已发生血清转化、PCR 定型 DEN-4 感染患者中的抗体发生反应。